New Protein Kinase CK2 Inhibitors: Jumping out of the Catalytic Box

Chemistry and Biology

Volumn 16, Issue 2, 2009, Pages 112-120

  Prudent, Renaud ^a   Cochet, Claude ^a  

^a INSERM   (France)

Author keywords

CHEMBIO; SIGNALING

Indexed keywords

CASEIN KINASE II; PROTEIN KINASE INHIBITOR;

ANIMAL; BINDING SITE; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; ENZYME SPECIFICITY; GENETICS; HUMAN; METABOLISM; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING SITES; CASEIN KINASE II; DRUG DESIGN; HUMANS; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 60849102173     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2009.01.004     Document Type: Review

References (77)

1. Adrian F.J., Ding Q., Sim T., Velentza A., Sloan C., Liu Y., Zhang G., Hur W., Ding S., Manley P., et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat. Chem. Biol. 2 (2006) 95-102
2. Bibby A.C., and Litchfield D.W. The multiple personalities of the regulatory subunit of protein kinase CK2: CK2 dependent and CK2 independent roles reveal a secret identity for CK2β. Int. J. Biol. Sci. 1 (2005) 67-79
3. Bogoyevitch M.A., and Fairlie D.P. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov. Today 12 (2007) 622-633
4. Buchou T., Vernet M., Blond O., Jensen H.H., Pointu H., Olsen B.B., Cochet C., Issinger O.G., and Boldyreff B. Disruption of the regulatory β subunit of protein kinase CK2 in mice leads to a cell-autonomous defect and early embryonic lethality. Mol. Cell. Biol. 23 (2003) 908-915
5. Burke J.R., Pattoli M.A., Gregor K.R., Brassil P.J., MacMaster J.F., McIntyre K.W., Yang X., Iotzova V.S., Clarke W., Strnad J., et al. BMS-345541 is a highly selective inhibitor of I κ B kinase that binds at an allosteric site of the enzyme and blocks NF-κ B-dependent transcription in mice. J. Biol. Chem. 278 (2003) 1450-1456
6. Castro A., Encinas A., Gil C., Brase S., Porcal W., Perez C., Moreno F.J., and Martinez A. Non-ATP competitive glycogen synthase kinase 3β (GSK-3β) inhibitors: study of structural requirements for thiadiazolidinone derivatives. Bioorg. Med. Chem. 16 (2008) 495-510
7. Chantalat L., Leroy D., Filhol O., Nueda A., Benitez M.J., Chambaz E.M., Cochet C., and Dideberg O. Crystal structure of the human protein kinase CK2 regulatory subunit reveals its zinc finger-mediated dimerization. EMBO J. 18 (1999) 2930-2940
8. Chiou S.H., Liu J.H., Hsu W.M., Chen S.S., Chang S.Y., Juan L.J., Lin J.C., Yang Y.T., Wong W.W., Liu C.Y., et al. Up-regulation of Fas ligand expression by human cytomegalovirus immediate-early gene product 2: a novel mechanism in cytomegalovirus-induced apoptosis in human retina. J. Immunol. 167 (2001) 4098-4103
9. Cohen P. The development and therapeutic potential of protein kinase inhibitors. Curr. Opin. Chem. Biol. 3 (1999) 459-465
10. Cohen P., and Goedert M. Engineering protein kinases with distinct nucleotide specificities and inhibitor sensitivities by mutation of a single amino acid. Chem. Biol. 5 (1998) R161-R164
11. Conde S., Perez D.I., Martinez A., Perez C., and Moreno F.J. Thienyl and phenyl α-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3β) from a library of compound searching. J. Med. Chem. 46 (2003) 4631-4633
12. Davidson W., Frego L., Peet G.W., Kroe R.R., Labadia M.E., Lukas S.M., Snow R.J., Jakes S., Grygon C.A., Pargellis C., and Werneburg B.G. Discovery and characterization of a substrate selective p38α inhibitor. Biochemistry 43 (2004) 11658-11671
13. Deshiere A., Theis-Febvre N., Martel V., Cochet C., and Filhol O. Protein kinase CK2 and cell polarity. Mol. Cell. Biochem. 316 (2008) 107-113
14. Duncan J.S., and Litchfield D.W. Too much of a good thing: The role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim. Biophys. Acta 1784 (2008) 33-47
15. Duncan J.S., Gyenis L., Lenehan J., Bretner M., Graves L.M., Haystead T.A., and Litchfield D.W. An unbiased evaluation of CK2 inhibitors by chemo-proteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets. Mol. Cell. Proteomics 7 (2008) 1077-1088
16. Escalier D., Silvius D., and Xu X. Spermatogenesis of mice lacking CK2α′: failure of germ cell survival and characteristic modifications of the spermatid nucleus. Mol. Reprod. Dev. 66 (2003) 190-201
17. Fabian M.A., Biggs III W.H., Treiber D.K., Atteridge C.E., Azimioara M.D., Benedetti M.G., Carter T.A., Ciceri P., Edeen P.T., Floyd M., et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23 (2005) 329-336
18. Faust M., and Montenarh M. Subcellular localization of protein kinase CK2. A key to its function?. Cell Tissue Res. 301 (2000) 329-340
19. Faust R.A., Tawfic S., Davis A.T., Bubash L.A., and Ahmed K. Antisense oligonucleotides against protein kinase CK2-α inhibit growth of squamous cell carcinoma of the head and neck in vitro. Head Neck 22 (2000) 341-346
20. Favata M.F., Horiuchi K.Y., Manos E.J., Daulerio A.J., Stradley D.A., Feeser W.S., Van Dyk D.E., Pitts W.J., Earl R.A., Hobbs F., et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273 (1998) 18623-18632
21. Filhol O., Nueda A., Martel V., Gerber-Scokaert D., Benitez M.J., Souchier C., Saoudi Y., and Cochet C. Live-cell fluorescence imaging reveals the dynamics of protein kinase CK2 individual subunits. Mol. Cell. Biol. 23 (2003) 975-987
22. Filhol O., Martiel J.L., and Cochet C. Protein kinase CK2: a new view of an old molecular complex. EMBO Rep. 5 (2004) 351-355
23. Glover C.V. A filamentous form of Drosophila casein kinase II. J. Biol. Chem. 261 (1986) 14349-14354
24. Glover III C.V. On the physiological role of casein kinase II in Saccharomyces cerevisiae. Prog. Nucleic Acid Res. Mol. Biol. 59 (1998) 95-133
25. Grein S., Raymond K., Cochet C., Pyerin W., Chambaz E.M., and Filhol O. Searching interaction partners of protein kinase CK2β subunit by two-hybrid screening. Mol. Cell. Biochem. 191 (1999) 105-109
26. Guerra B., Siemer S., Boldyreff B., and Issinger O.G. Protein kinase CK2: evidence for a protein kinase CK2β subunit fraction, devoid of the catalytic CK2α subunit, in mouse brain and testicles. FEBS Lett. 462 (1999) 353-357
27. Gumireddy K., Baker S.J., Cosenza S.C., John P., Kang A.D., Robell K.A., Reddy M.V., and Reddy E.P. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc. Natl. Acad. Sci. USA 102 (2005) 1992-1997
28. Gumireddy K., Reddy M.V., Cosenza S.C., Boominathan R., Baker S.J., Papathi N., Jiang J., Holland J., and Reddy E.P. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7 (2005) 275-286
29. Han S., Zhou V., Pan S., Liu Y., Hornsby M., McMullan D., Klock H.E., Haugen J., Lesley S.A., Gray N., et al. Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors. Bioorg. Med. Chem. Lett. 15 (2005) 5467-5473
30. Hopkins A.L., and Groom C.R. The druggable genome. Nat. Rev. Drug Discov. 1 (2002) 727-730
31. Kerkela R., Grazette L., Yacobi R., Iliescu C., Patten R., Beahm C., Walters B., Shevtsov S., Pesant S., Clubb F.J., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 12 (2006) 908-916
32. Kim J.S., Eom J.I., Cheong J.W., Choi A.J., Lee J.K., Yang W.I., and Min Y.H. Protein kinase CK2α as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia. Clin. Cancer Res. 13 (2007) 1019-1028
33. Klein S., McCormick F., and Levitzki A. Killing time for cancer cells. Nat. Rev. Cancer 5 (2005) 573-580
34. Knight Z.A., and Shokat K.M. Features of selective kinase inhibitors. Chem. Biol. 12 (2005) 621-637
35. Krause D.S., and Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353 (2005) 172-187
36. Ladbury J.E., Lemmon M.A., Zhou M., Green J., Botfield M.C., and Schlessinger J. Measurement of the binding of tyrosyl phosphopeptides to SH2 domains: a reappraisal. Proc. Natl. Acad. Sci. USA 92 (1995) 3199-3203
37. Laramas M., Pasquier D., Filhol O., Ringeisen F., Descotes J.L., and Cochet C. Nuclear localization of protein kinase CK2 catalytic subunit (CK2α) is associated with poor prognostic factors in human prostate cancer. Eur. J. Cancer 43 (2007) 928-934
38. Laudet B., Barette C., Dulery V., Renaudet O., Dumy P., Metz A., Prudent R., Deshiere A., Dideberg O., Filhol O., and Cochet C. Structure-based design of small peptide inhibitors of protein kinase CK2 subunit interaction. Biochem. J. 408 (2007) 363-373
39. Laudet B., Moucadel V., Prudent R., Filhol O., Wong Y.S., Royer D., and Cochet C. Identification of chemical inhibitors of protein-kinase CK2 subunit interaction. Mol. Cell. Biochem. 316 (2008) 63-69
40. Leroy D., Valero E., Filhol O., Heriche J.K., Goldberg Y., Chambaz E.M., and Cochet C. Modulation of the molecular organization and activity of casein kinase 2 by naturally occurring polyamines. Cell. Mol. Biol. Res. 40 (1994) 441-453
41. Lindsley C.W., Zhao Z., Leister W.H., Robinson R.G., Barnett S.F., Defeo-Jones D., Jones R.E., Hartman G.D., Huff J.R., Huber H.E., and Duggan M.E. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett. 15 (2005) 761-764
42. Litchfield D.W. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem. J. 369 (2003) 1-15
43. Lou D.Y., Dominguez I., Toselli P., Landesman-Bollag E., O'Brien C., and Seldin D.C. The α catalytic subunit of protein kinase CK2 is required for mouse embryonic development. Mol. Cell. Biol. 28 (2008) 131-139
44. Manley P.W., Bold G., Bruggen J., Fendrich G., Furet P., Mestan J., Schnell C., Stolz B., Meyer T., Meyhack B., et al. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim. Biophys. Acta 1697 (2004) 17-27
45. Martel V., Filhol O., Colas P., and Cochet C. p53-dependent inhibition of mammalian cell survival by a genetically selected peptide aptamer that targets the regulatory subunit of protein kinase CK2. Oncogene 25 (2006) 7343-7353
46. Medina-Palazon C., Gruffat H., Mure F., Filhol O., Vingtdeux-Didier V., Drobecq H., Cochet C., Sergeant N., Sergeant A., and Manet E. Protein kinase CK2 phosphorylation of EB2 regulates its function in the production of Epstein-Barr virus infectious viral particles. J. Virol. 81 (2007) 11850-11860
47. Meggio F., Pagano M.A., Moro S., Zagotto G., Ruzzene M., Sarno S., Cozza G., Bain J., Elliott M., Deana A.D., et al. Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo study. Biochemistry 43 (2004) 12931-12936
48. Niefind K., and Issinger O.G. Primary and secondary interactions between CK2α and CK2β lead to ring-like structures in the crystals of the CK2 holoenzyme. Mol. Cell. Biochem. 274 (2005) 3-14
49. Niefind K., Guerra B., Ermakowa I., and Issinger O.G. Crystal structure of human protein kinase CK2: insights into basic properties of the CK2 holoenzyme. EMBO J. 20 (2001) 5320-5331
50. Nuesch J.P., and Rommelaere J. A viral adaptor protein modulating casein kinase II activity induces cytopathic effects in permissive cells. Proc. Natl. Acad. Sci. USA 104 (2007) 12482-12487
51. O-charoenrat P., Rusch V., Talbot S.G., Sarkaria I., Viale A., Socci N., Ngai I., Rao P., and Singh B. Casein kinase II α subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung. Clin. Cancer Res. 10 (2004) 5792-5803
52. Ohren J.F., Chen H., Pavlovsky A., Whitehead C., Zhang E., Kuffa P., Yan C., McConnell P., Spessard C., Banotai C., et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol. 11 (2004) 1192-1197
53. Pagano M.A., Andrzejewska M., Ruzzene M., Sarno S., Cesaro L., Bain J., Elliott M., Meggio F., Kazimierczuk Z., and Pinna L.A. Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J. Med. Chem. 47 (2004) 6239-6247
54. Pargellis C., Tong L., Churchill L., Cirillo P.F., Gilmore T., Graham A.G., Grob P.M., Hickey E.R., Moss N., Pav S., and Regan J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 9 (2002) 268-272
55. Perea S.E., Reyes O., Puchades Y., Mendoza O., Vispo N.S., Torrens I., Santos A., Silva R., Acevedo B., Lopez E., et al. Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2). Cancer Res. 64 (2004) 7127-7129
56. Perea S.E., Reyes O., Baladron I., Perera Y., Farina H., Gil J., Rodriguez A., Bacardi D., Marcelo J.L., Cosme K., et al. CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo. Mol. Cell. Biochem. 316 (2008) 163-167
57. Perera Y., Farina H.G., Hernandez I., Mendoza O., Serrano J.M., Reyes O., Gomez D.E., Gomez R.E., Acevedo B.E., Alonso D.F., and Perea S.E. Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice. Int. J. Cancer 122 (2008) 57-62
58. Pinna L.A. Protein kinase CK2: a challenge to canons. J. Cell Sci. 115 (2002) 3873-3878
59. Prudent R., Moucadel V., Laudet B., Barette C., Lafanechere L., Hasenknopf B., Li J., Bareyt S., Lacote E., Thorimbert S., et al. Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2. Chem. Biol. 15 (2008) 683-692
60. Pope M.T. Introduction to polyoxometalate chemistry. In: Borras-Almenar J.J., Coronado E., Muller A., and Pope M.T. (Eds). Polyoxometalate Molecular Science (2003), Kluwer Academic Publishers, Dordrecht 3-31
61. Raaf J., Brunstein E., Issinger O.G., and Niefind K. The CK2α/CK2β interface of human protein kinase CK2 harbors a binding pocket for small molecules. Chem. Biol. 15 (2008) 111-117
62. Sarno S., Ghisellini P., and Pinna L.A. Unique activation mechanism of protein kinase CK2. The N-terminal segment is essential for constitutive activity of the catalytic subunit but not of the holoenzyme. J. Biol. Chem. 277 (2002) 22509-22514
63. Sarno S., de Moliner E., Ruzzene M., Pagano M.A., Battistutta R., Bain J., Fabbro D., Schoepfer J., Elliott M., Furet P., et al. Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA). Biochem. J. 374 (2003) 639-646
64. Shimada K., Kondo K., and Yamanishi K. Human herpesvirus 6 immediate-early 2 protein interacts with heterogeneous ribonucleoprotein K and casein kinase 2. Microbiol. Immunol. 48 (2004) 205-210
65. Siu T., Li Y., Nagasawa J., Liang J., Tehrani L., Chua P., Jones R.E., Defeo-Jones D., Barnett S.F., and Robinson R.G. The design and synthesis of potent and cell-active allosteric dual Akt 1 and 2 inhibitors devoid of hERG activity. Bioorg. Med. Chem. Lett. 18 (2008) 4191-4194
66. Slaton J.W., Unger G.M., Sloper D.T., Davis A.T., and Ahmed K. Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model. Mol. Cancer Res. 2 (2004) 712-721
67. Souquere-Besse S., Pichard E., Filhol O., Legrand V., Rosa-Calatrava M., Hovanessian A.G., Cochet C., and Puvion-Dutilleul F. Adenovirus infection targets the cellular protein kinase CK2 and RNA- activated protein kinase (PKR) into viral inclusions of the cell nucleus. Microsc. Res. Tech. 56 (2002) 465-478
68. Spicer J.A., Rewcastle G.W., Kaufman M.D., Black S.L., Plummer M.S., Denny W.A., Quin III J., Shahripour A.B., Barrett S.D., Whitehead C.E., et al. 4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase. J. Med. Chem. 50 (2007) 5090-5102
69. Steiner L., Blum G., Friedmann Y., and Levitzki A. ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents. Eur. J. Pharmacol. 562 (2007) 1-11
70. Tawfic S., Yu S., Wang H., Faust R., Davis A., and Ahmed K. Protein kinase CK2 signal in neoplasia. Histol. Histopathol. 16 (2001) 573-582
71. Valero E., De Bonis S., Filhol O., Wade R.H., Langowski J., Chambaz E.M., and Cochet C. Quaternary structure of casein kinase 2. Characterization of multiple oligomeric states and relation with its catalytic activity. J. Biol. Chem. 270 (1995) 8345-8352
72. Vangrevelinghe E., Zimmermann K., Schoepfer J., Portmann R., Fabbro D., and Furet P. Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking. J. Med. Chem. 46 (2003) 2656-2662
73. Wadd S., Bryant H., Filhol O., Scott J.E., Hsieh T.Y., Everett R.D., and Clements J.B. The multifunctional herpes simplex virus IE63 protein interacts with heterogeneous ribonucleoprotein K and with casein kinase 2. J. Biol. Chem. 274 (1999) 28991-28998
74. Wang H., Davis A., Yu S., and Ahmed K. Response of cancer cells to molecular interruption of the CK2 signal. Mol. Cell. Biochem. 227 (2001) 167-174
75. Wilhelm S., Carter C., Lynch M., Lowinger T., Dumas J., Smith R.A., Schwartz B., Simantov R., and Kelley S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5 (2006) 835-844
76. Yde C.W., Frogne T., Lykkesfeldt A.E., Fichtner I., Issinger O.G., and Stenvang J. Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT. Cancer Lett. 256 (2007) 229-237
77. Zhou M.M., Harlan J.E., Wade W.S., Crosby S., Ravichandran K.S., Burakoff S.J., and Fesik S.W. Binding affinities of tyrosine-phosphorylated peptides to the COOH-terminal SH2 and NH2-terminal phosphotyrosine binding domains of Shc. J. Biol. Chem. 270 (1995) 31119-31123